Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.
The FDA has approved datopotamab deruxtecan (Dato-DXd, Datroway, Daiichi Sankyo) for the treatment of patients with ...
Semaglutide and tirzepatide use is rising among patients with rheumatic and musculoskeletal diseases and is linked to meaningful 1-year weight loss, especially in tirzepatide users.
The Fracture Risk Assessment Tool predictions suggest patients who don’t meet guideline criteria for parathyroidectomy may ...
Emerging evidence suggests some sugar substitutes may affect metabolism, gut microbiome, and cardiovascular health more than ...
Pierre de Brémond d’Ars, a French GP who leads the evidence-based medicine group NoFakeMed, tells Medscape’s French edition ...
Higher dermatologist density is associated with lower proportions of late stage melanoma diagnosis across US health service ...
The conditional authorization covers adults and children aged 2 years and older with severe or life-threatening ...
A lightweight robotic knee device improves strength, muscle growth, and standing ability in children with SMA, with benefits ...
Dr Sunnie Kim previews key GI trials highlighting novel bispecific antibodies, dual immunotherapy combinations, KIT ...
A cohort study of births in Brazil found increased hospitalization risk through age 3 after maternal chikungunya; results ...
Researchers have identified a compound produced by a variety of land snail that prevents blood clots without prolonging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results